2. Search Result
Search Result
Results for "

potentiator

" in MedChemExpress (MCE) Product Catalog:

46

Inhibitors & Agonists

6

Peptides

3

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3985
    Bradykinin potentiator B

    Bradykinin potentiating peptide B

    		 Angiotensin-converting Enzyme (ACE) Others
    Bradykinin potentiator B (Bradykinin potentiating peptide B) is venom of Agkistrodon halys blomhoffi. Bradykinin potentiator B is a potent ACE inhibitor. Bradykinin potentiator inhibits the activity of bradykinin inhibitory peptidase .
    Bradykinin <em>potentiator</em> B
  • HY-108450
    Polygodial

    Poligodial; Tadeonal

    		 Fungal Infection Inflammation/Immunology
    Polygodial (Poligodial) is an antifungal potentiator . Polygodial is a sesquiterpene with anti-hyperalgesic properties .
    Polygodial
  • HY-15442
    Biphenylindanone A

    BINA

    		 mGluR Neurological Disease
    Biphenylindanone A (BINA) is a selective human mGluR2 (hmGluR2) potentiator for the treatment of many neurological disorders .
    Biphenylindanone A
  • HY-147352
    NMDA receptor potentiator-1

    		iGluR Neurological Disease
    NMDA receptor potentiator-1 (Compound 1368) is a subunit selective NMDA receptor potentiator with IC50s of 4 μM and 5 μM against NR2C and NR2D expression, respectively .
    NMDA receptor <em>potentiator</em>-1
  • HY-P3991
    Bradykinin potentiator C

    		Angiotensin-converting Enzyme (ACE) Metabolic Disease
    Bradykinin potentiator C is a potent angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 7.1 μM for rabbit lung ACE. Bradykinin potentiator C is a postulated prototype of functional peptide .
    Bradykinin <em>potentiator</em> C
  • HY-117517
    NG-012

    		Others Cancer
    NG-012, potentiator of nerve growth factor (NGF), were isolated from the culture broth of Penicillium verruculosum F-4542. NG-012 potentiates the neurite outgrowth induced by NGF in rat pheochromocytoma cell line (PC12) .
    NG-012
  • HY-113319
    β-D-Fructose

    		Endogenous Metabolite Cancer
    β-D-Fructose is a β-fruit sugar that can be produced by the hydrolysis of sucrose. β-D-Fructose can be used as a sweetness potentiator. β-D-Fructose can be designed as a units of antiproliferative agents against breast (MCF-7) and colon (MDST8) cancer cell lines .
    β-D-Fructose
  • HY-149861
    Mip-IN-1

    		Others Infection
    Mip-IN-1（S,S-28i）is a new rapamycin-derived macrophage infectivity potentiator (Mip) inhibitor. Mip-IN-1 displays strong anti-enzymatic activity against the Mip proteins of Neisseria meningitidis and Neisseria gonorrhoeae and substantially improved the ability of macrophages to kill the bacteria .
    Mip-IN-1
  • HY-P1649B
    SPR741 acetate
    2 Publications Verification

    NAB741 acetate

    		 Bacterial Antibiotic Infection
    SPR741 acetate (NAB741 acetate) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 acetate increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative bacteria infections. SPR741 acetate inhibits multidrug-resistant Gram-negative bacteria. The spectrum of activity of the antibiotic can be widened when used in combination with SPR741 acetate .
    SPR741 acetate
  • HY-P1649
    SPR741

    NAB741

    		 Bacterial Antibiotic Infection
    SPR741 (NAB741) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative bacteria infections. SPR741 inhibits multidrug-resistant Gram-negative bacteria. The spectrum of activity of the antibiotic can be widened when used in combination with SPR741 .
    SPR741
  • HY-P1649A
    SPR741 TFA

    NAB741 TFA

    		 Bacterial Antibiotic Infection
    SPR741 TFA (NAB741 TFA) is a cationic peptide derived from polymyxin B and is a potentiator molecule. SPR741 TFA increases the permeability of the outer membrane of Gram-negative bacteria and is used to treat severe Gram-negative bacteria infections. SPR741 TFA inhibits multidrug-resistant Gram-negative bacteria. The spectrum of activity of the antibiotic can be widened when used in combination with SPR741 TFA .
    SPR741 TFA
  • HY-103369
    PG01

    		CFTR Endocrinology
    PG01 is a potent CFTR Cl - channel potentiator. PG01 can correct gating defects of CFTR mutants, is effective on b>E193K, G970R and G551D (CFTR mutants) with Kd values of 0.22 μM, 0.45 μM and 1.94 μM, respectively. PG01 is also effective on ΔF508 (Ka of 0.3 μM). PG01 increases ΔF508-CFTR Cl - current after adding Forskolin .
    PG01
  • HY-10934
    Mibampator

    LY451395

    		 iGluR Neurological Disease
    Mibampator (LY451395) is a potent and highly selective potentiator of the AMPA receptors.
    Mibampator
  • HY-13017A
    Ivacaftor benzenesulfonate

    VX-770 benzenesulfonate

    		 CFTR Autophagy Endocrinology
    Ivacaftor benzenesulfonate is an orally bioavailable CFTR potentiator, used for cystic fibrosis treatment.
    Ivacaftor benzenesulfonate
  • HY-B1056
    Procodazole

    Propazol; 2-Benzimidazolepropionic acid

    		 Bacterial Infection
    Procodazole is a non-specific active immunoprotective agent against viral and bacterial infections, used as a potentiator.
    Procodazole
  • HY-13017B
    Ivacaftor hydrate

    VX-770 hydrate

    		 CFTR Autophagy Endocrinology
    Ivacaftor hydrate (VX-770 hydrate) is an orally bioavailable CFTR potentiator, used for cystic fibrosis treatment.
    Ivacaftor hydrate
  • HY-139715
    IMD-ferulic

    		NF-κB Cancer
    IMD-ferulic is a covalently linked NF-κB modulator that improves the adjuvanticity of small molecule immune potentiators.
    IMD-ferulic
  • HY-18699
    CIQ
    1 Publications Verification

    		 iGluR Neurological Disease
    CIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit.
    CIQ
  • HY-139717
    IMD-biphenylA

    		NF-κB Cancer
    IMD-biphenylA is a novel imidazoquinolinone-NF-κB immunomodulator dimer that improves the adjuvanticity of small molecule immune potentiators.
    IMD-biphenylA
  • HY-10935
    LY450108
    1 Publications Verification

    		 iGluR Neurological Disease
    LY450108 is a potent AMPA receptor potentiator. LY450108 has the potential for depression and Parkinson's disease research .
    LY450108
  • HY-112781
    Pesampator

    PF-04958242

    		 iGluR Neurological Disease
    Pesampator (PF-04958242) is a potent and highly selective positive allosteric modulator of AMPA receptor (an AMPA potentiator) with an EC50 of 310 nM and a Ki of 170 nM .
    Pesampator
  • HY-111099
    GLPG1837

    ABBV-974

    		 CFTR Autophagy Others
    GLPG1837 is a potent and reversible CFTR potentiator, with EC50s of 3 nM and 339 nM for F508del and G551D CFTR, respectively.
    GLPG1837
  • HY-145126
    CP-628006

    		CFTR Others
    CP-628006, a small molecule CFTR potentiator, restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR.
    CP-628006
  • HY-147367
    AM-1488

    		Others Neurological Disease
    AM-1488 is a potent, orally active glycine receptor (GlyR) potentiator (hGlyRα3 EC50=0.45 μM) .
    AM-1488
  • HY-119936
    GLPG2451

    		CFTR Autophagy Inflammation/Immunology
    GLPG2451 is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, which effectively potentiates low temperature rescued F508del CFTR with an EC50 of 11.1 nM .
    GLPG2451
  • HY-136939
    CFTR corrector 6

    		CFTR Metabolic Disease Inflammation/Immunology
    CFTR corrector 6 is a potent potentiator of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). CFTR corrector 6 has the potential for cystic fibrosis (CF) and other CFTR associated disorders research .
    CFTR corrector 6
  • HY-107683
    LY-2087101

    		nAChR Neurological Disease
    LY-2087101 is an allosteric potentiator of α7 nAChRs. LY-2087101 causes potentiation of agonist-evoked α7 responses by binding within the nAChR transmembrane region .
    LY-2087101
  • HY-134598A
    653-47 hydrochloride

    		Epigenetic Reader Domain Cancer
    653-47 hydrochloride, a potentiator, significantly potentiates the cAMP-response element binding protein (CREB) inhibitory activity of 666-15. 653-47 hydrochloride is also a very weak CREB inhibitor with IC50 of 26.3 μM .
    653-47 hydrochloride
  • HY-134598
    653-47

    		Epigenetic Reader Domain Cancer
    653-47, a potentiator, significantly potentiates the cAMP-response element binding protein (CREB) inhibitory activity of 666-15. 653-47 is also a very weak CREB inhibitor with IC50 of 26.3 μM .
    653-47
  • HY-13017
    Ivacaftor
    5 Publications Verification

    VX-770

    		 CFTR Autophagy Endocrinology
    Ivacaftor (VX-770) is a potent and orally bioavailable CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC50s of 100 nM and 25 nM, respectively.
    Ivacaftor
  • HY-139718
    IMD-biphenylB

    		NF-κB Inflammation/Immunology
    IMD-biphenylB is a potent imidazoquinolinone-NF-κB immunomodulator dimer that inhibits tumor proliferation while induces low systemic inflammation and reduces adjuvant toxicity.
    IMD-biphenylB
  • HY-143891
    Chromenone 1

    		TGF-β Receptor Others
    Chromenone 1 is a potent osteogenic bone morphogenetic protein (BMP) potentiator. Chromenone 1 exhibits a unique mode of action as it induces a pronounced, kinase-independent, negative TGFβ feedback that enhances nuclear BMP-Smad signaling outputs .
    Chromenone 1
  • HY-109177
    Icenticaftor

    QBW251

    		 CFTR Inflammation/Immunology
    Icenticaftor (QBW251) is an orally active CFTR channel potentiator, with EC50s of 79 nM and 497 nM for F508del and G551D CFTR, respectively. Icenticaftor can be used for chronic obstructive pulmonary disease (COPD) and cystic fibrosis research .
    Icenticaftor
  • HY-116152S
    Cipepofol-d6

    Ciprofol-d6; HSK3486-d6

    		 Isotope-Labeled Compounds GABA Receptor Neurological Disease
    Cipepofol-d6 (Ciprofol-d6; HSK3486-d6) is deuterium labeled Cipepofol (HY-116152). Cipepofol (HSK3486), a psychomotor stabilizing agent, is a gamma-aminobutyric acid (GABA) receptor potentiator.
    Cipepofol-d6
  • HY-107508
    VU-29

    		mGluR Neurological Disease
    VU-29 is a positive allosteric modulator of metabotropic glutamate 5 (mGlu5) receptor (EC50=9 nM and Ki=244 nM for rmGluR5). VU-29 is selective for mGluR5 relative to other mGluR subtypes (EC50: rmGluR1/rmGluR2=557 nM/1.5 μM; hmGluR4=154 nM) .
    VU-29
  • HY-116152S2
    Cipepofol-d6-2

    Ciprofol-d6-2; HSK3486-d6-2

    		 Isotope-Labeled Compounds GABA Receptor Neurological Disease
    Cipepofol-d6-2 (Ciprofol-d6-2; HSK3486-d6-2) is deuterium labeled Cipepofol (HY-116152). Cipepofol (HSK3486), a psychomotor stabilizing agent, is a gamma-aminobutyric acid (GABA) receptor potentiator.
    Cipepofol-d6-2
  • HY-14563
    VU10010

    		mAChR Neurological Disease
    VU10010 is a potent, highly selective and allosteric M4 mAChR potentiator with an EC50 of 400 nM. VU10010 binds to an allosteric site on M4 mAChR and increases affinity for acetylcholine and coupling to G proteins. VU10010 increases carbachol-induced depression of transmission at excitatory but not inhibitory synapses in the hippocampus .
    VU10010
  • HY-107701
    CGP 78608 hydrochloride

    		iGluR Neurological Disease
    CGP 78608 hydrochloride is a highly potent and selective antagonist at the glycine-binding site of the NMDA receptor, with an IC50 of 6 nM. CGP 78608 acts as a potentiator of GluN1/GluN3A-mediated glycine currents, with an estimated EC50 in the low nM range (26.3 nM). Anticonvulsant activity .
    CGP 78608 hydrochloride
  • HY-13017S2
    Ivacaftor-d18

    VX-770-d18

    		 Autophagy CFTR Endocrinology
    Ivacaftor-d18 is the deuterium labeled Ivacaftor[1]. Ivacaftor (VX-770) is a potent and orally bioavailable CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC50s of 100 nM and 25 nM, respectively[2].
    Ivacaftor-d18
  • HY-150650
    S07-2001

    		Others Cancer
    S07-2001 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 2.08 μM. S07-2001 enhances the activity of Doxorubicin against cancer cells. S07-2001 has potential as a chemotherapeutic potentiator for cancer agent resistance .
    S07-2001
  • HY-13017S3
    Ivacaftor-d4

    VX-770-d4

    		 CFTR Endocrinology
    Ivacaftor-d4 (VX-770-d4) is the deuterium labeled-Ivacaftor (HY-13017). Ivacaftor is a potent and orally active CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC50s of 100 nM and 25 nM, respectively .
    Ivacaftor-d4
  • HY-16654
    ML254

    		mGluR Neurological Disease
    ML254 is a potent mGlu5 potentiator, with EC50 and pEC50 of 9.3 nM and 8.03 nM for rat mGlu5, respectively. ML254 can be used for researching schizophrenia . ML254 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    ML254
  • HY-150649
    S07-2005 (racemic)

    		Others Cancer
    S07-2005 racemic is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 0.13 μM and 0.75 μM for AKR1C3 and AKR1C4, respectively. S07-2005 racemic has potential as a chemotherapeutic potentiator for cancer agent resistance .
    S07-2005 (racemic)
  • HY-115553
    DETQ

    		Dopamine Receptor Neurological Disease
    DETQ is a selective, allosteric and orally active dopamine D1 receptor (Dopamine Receptor) potentiator. In HEK293 cells expressing the human D1 receptor, DETQ increases cAMP with an EC50 of 5.8 nM and a Kb of 26 nM. DETQ shows ~30-fold less potent at rat and mouse D1 receptors and is inactive at the human D5 receptor .
    DETQ
  • HY-122742
    HBT1

    		iGluR Neurological Disease
    HBT1 is a potent α-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor (AMPA-R) potentiator. HBT1 bonds with S518 in the ligand-binding domain (LBD) of AMPA-R in a glutamate-dependent manner. HBT1 did not show remarkable bell-shaped response in brain-derived neurotrophic factor (BDNF) production in primary neurons .
    HBT1
  • HY-15448
    Tezacaftor
    Maximum Cited Publications
    8 Publications Verification

    VX-661

    		 CFTR Cancer
    Tezacaftor (VX-661) is a F508del CFTR corrector. It helps CFTR protein reach the cell surface. However, Ivacaftor (VX-770, HY-13017), a CFTR potentiator, helps to prolong the opening time of cell surface CFTR protein channels. Tezacaftor combining with Ivacaftor, shows potent efficacy against cystic fibrosis and diseases with homozygous for the CFTR Phe508del mutation. Moreover, Elexacaftor (VX-445, HY-111772) is also a CFTR corrector. Elexacaftor-Tezacaftor-Ivacaftor aims at with cystic fibrosis (CF) with at least one Phe508del mutation, often avoids the indication for lung transplantation .
    Tezacaftor

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: